Patients with metastatic breast cancer receiving HER2-targeted therapies should promptly report any respiratory symptoms or signs of lung and heart disease to their oncology care team to facilitate early intervention and management of side effects.
Patients with metastatic breast cancer receiving HER2-targeted therapies should promptly report any respiratory symptoms or signs of lung and heart disease to their oncology care team to facilitate early intervention and management of side effects.
